The W. Garfield Weston Foundation – Michael J. Fox Foundation Grants

The Weston Brain Institute has supported various collaborations with the Michael J. Fox Foundation. The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today. The funds from these collaborations have been used to help accelerate 8 Canada-based research efforts.

Proof of concept of treatment with novel hydroxypyridinone iron chelators in a non-clinical model of Parkinson’s disease

Grantees: Dr. Jolanta Wodzinska

Project description The two iron chelators will be studied in a chronic, toxin-induced pre-clinical model of PD, which features selective degeneration of dopaminergic neurons, brain iron accumulation, and oxidative...


Testing of davunetide for intranasal administration in a pre-clinical model over-expressing alpha synuclein

Grantees: Dr. Bruce H. Morimoto

Project description Previously, in a study sponsored by MJFF, the investigators found that treatment with davunetide for two months resulted in an impact on brain pathology as evidenced by...


Intermittent bilateral intraputamenal treatment with GDNF

Grantees: Dr. Erich Mohr

Project description Researchers have developed a novel approach to delivering GDNF to the putamen by a process called convection-enhanced delivery (CED). This approach is aimed to optimize drug distribution...


Developing a human neural model for Parkinson’s disease

Grantees: Dr. Matthew Olding Hebb

Project description PD patients selected for deep brain stimulation will be invited to participate in this research. Cortical biopsies will be retrieved in the operating room and immediately processed...


Delayed start assessment of progranulin in a progressive rodent model of PD

Grantees: Dr. Denis Kay

Project description Here we propose to test the more clinically relevant treatment scenario of intervening with progranulin therapy after disease has been established, in a progressive pre-clinical model of...


Development of trehalose as a disease-modifying treatment for Parkinson’s disease

Grantees: Dr. James Koprich

Project description We will identify blood and brain levels of trehalose associated with efficacy in an alpha-synuclein model of PD and define dosing strategies to translate these levels to...


Validation of sirtuin 3 as a neuroprotective target in Parkinson’s disease

Grantees: Dr. Joanne Nash

Project description To measure the neuroprotective value of SIRT3, one of the few pre-clinical models shown to exhibit pathological and behavioral abnormalities equivalent to those observed in PD patients...


Development of L-745,870, a selective D4 receptor antagonist, for the treatment of levodopa-induced dyskinesia

Grantees: Dr. Jonathan Brotchie

Project description Levodopa-induced dyskinesia remains one of the major factors limiting the usefulness of current treatments for Parkinson’s disease. The program has potential to provide a pharmacological means to...